Literature DB >> 15223524

Factors associated with efavirenz discontinuation in a large community-based sample of patients.

B Spire1, P Carrieri, M-A Garzot, M L'henaff, Y Obadia.   

Abstract

Efavirenz (EFV) is a potent antiretroviral drug; its use may be limited, however, by psychiatric symptoms that require its discontinuation. We sought to identify the characteristics that placed patients at an elevated risk of discontinuation. Data for this cross-sectional study came from a self-administered questionnaire distributed by French AIDS community associations; it collected information about sociodemographic characteristics, addictive behaviours, treatment regimens, EFV history and depression. Patients remaining on EFV for more than six months were compared with those who stopped taking it. Of the 828 patients who completed the questionnaire, 175 had taken EFV for at least six months, and 152 had discontinued it (median months [IQR] of exposure=4[2-10]). Of these 327 patients (median age=42), 23% were women, 46% were unemployed, 38% had a steady sexual partner and 24% reported a history of multiple depressive episodes. Logistic regression showed that the factors independently associated with EFV discontinuation were female gender (OR[95%CI]=2.2[1.2-3.8]), unemployment (1.8[1.1-2.8]), a steady sexual partner (1.7[1-2.5]) and multiple episodes of depression (2.6[1.5-4.5]). Clinicians should keep in mind the neuropsychiatric risks of EFV during the first year, especially among patients with a history of multiple depressive episodes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223524     DOI: 10.1080/09540120410001716342

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  21 in total

1.  Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Authors:  David Burger; Ilse van der Heiden; Charles la Porte; Marchina van der Ende; Paul Groeneveld; Clemens Richter; Peter Koopmans; Frank Kroon; Herman Sprenger; Jan Lindemans; Paul Schenk; Ron van Schaik
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

2.  Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

Authors:  Rubin Lubomirov; Sara Colombo; Julia di Iulio; Bruno Ledergerber; Raquel Martinez; Matthias Cavassini; Bernard Hirschel; Enos Bernasconi; Luigia Elzi; Pietro Vernazza; Hansjakob Furrer; Huldrych F Günthard; Amalio Telenti
Journal:  J Infect Dis       Date:  2010-12-09       Impact factor: 5.226

Review 3.  Affective disorders in patients with HIV infection: impact of antiretroviral therapy.

Authors:  Gabriele Arendt
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.

Authors:  E Jennifer Edelman; Kirsha Gordon; Maria C Rodriguez-Barradas; Amy C Justice
Journal:  AIDS Patient Care STDS       Date:  2012-05-21       Impact factor: 5.078

Review 5.  Neuropsychiatric Effects of HIV Antiviral Medications.

Authors:  Glenn J Treisman; Olivia Soudry
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

6.  Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.

Authors:  Alison J Hughes; Christine L Mattson; Susan Scheer; Linda Beer; Jacek Skarbinski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

Review 7.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

8.  Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.

Authors:  Isaac Okoh Abah; Maxwell Akanbi; Mercy Enuwa Abah; Amos Istifanus Finangwai; Christy W Dady; Kakjing Dadul Falang; Augustine Odoh Ebonyi; Joseph Anejo Okopi; Oche Ochai Agbaji; Altiene Solomon Sagay; Prosper Okonkwo; John A Idoko; Phyllis J Kanki
Journal:  Germs       Date:  2015-09-01

9.  Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Authors:  Shaheena Asad; Todd Hulgan; Stephen P Raffanti; Jim Daugherty; Wayne Ray; Timothy R Sterling
Journal:  J Natl Med Assoc       Date:  2008-12       Impact factor: 1.798

10.  How do outcomes compare between women and men living with HIV in Australia? An observational study.

Authors:  Michelle L Giles; Marin C Zapata; Stephen T Wright; Kathy Petoumenos; Miriam Grotowski; Jennifer Broom; Matthew G Law; Catherine C O'Connor
Journal:  Sex Health       Date:  2016-04       Impact factor: 2.706

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.